Ther­a­pix Bio in the hunt for $12M mi­cro IPO; Prog­en­ics bags $50M loan; Juno is­n't go­ing any­where, for now

A low pro­file Is­raeli biotech named Ther­a­pix Bio­sciences is tak­ing a fli­er on a mi­cro IPO on NAS­DAQ. The biotech has done some pre­clin­i­cal work on a com­bi­na­tion of low dose dron­abi­nol, an ap­proved syn­thet­ic cannabi­noid, with palmi­toylethanolamide, or PEA, an en­doge­nous fat­ty acid amide for treat­ing Tourette syn­drome. The biotech is look­ing to raise about $12 mil­lion, the lat­est in a se­ries of mi­cro IPOs that have been mak­ing the rounds re­cent­ly as the IPO win­dow has nar­rowed con­sid­er­ably over the course of the year. Here’s the F-1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER